Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Genotyping improves accuracy of pancreatic cancer tumor markers

Key clinical point: Stratifying tumor marker cut-off levels based on genetic variants may improve detection of pancreatic cancer.

Major finding: Stratifying carbohydrate antigen 19-9 (CA19-9) cut-off levels by single-nucleotide polymorphisms (SNPs) provided a sensitivity of 60.8%, compared with 52.7% without stratification.

Study details: An observational prospective study involving 504 patients at high risk of pancreatic cancer and 245 patients with pancreatic cancer.

Disclosures: The study was funded by the National Institutes of Health, Susan Wojcicki and Dennis Troper, the Pancreatic Cancer Action Network, and others. The investigators reported no conflicts of interest.

Citation:

Abe T et al. Clin Gastro Hepatol. 2019 Oct 29. doi: 10.1016/j.cgh.2019.10.036.